Archive | March, 2014

Large Cap Biopharmaceutical Stocks Will Lead The Way Up

Large Cap Biopharmaceutical Growth Stocks  With the MoMo days over the next earnings cycle (Q1,Q2 2014) should give us better clarity on winners for 2014.On the last day of March all of these large caps rallied after a severe one week correction from 3/21-28. Watch the technicals this week for bargain hunting, for example, Amgen, […]

Continue Reading 0

Biotechs Weaker As Day Wears On: Counter-trend Green Movers

12:15p EDT  3/26 With NASDAQ down 0.64% and the IBB down 0.6% here are some green stocks: Rayno Life Science Portfolio:  AMGN up 0.53%, CPHD up 1.43%,  GILD up 0.57%, and REGN up 0.84%. Other Notables on our watch list:  CLVS up 4%, CONX up 11%, FMI up 2.7%, KERX up 17%, NSPH up 1.9%, […]

Continue Reading 0

Biotech Stocks Holding At February Lows- Still Up 9% YTD

(See Full Article in Seeking Alpha 3/26) Biopharmaceutical Downdraft 15% From February Highs (IBB$239) Large Cap Biopharmaceutical Stocks Are Core Holdings: ABBV, AMGN, GILD The biotech frenzy of MoMo investing is over so it is time to invest longer term with quality companies. If the sector can hold at February lows, even treading water could […]

Continue Reading 0

Alert: Broad Biotech Sell-Off of 4-5% ..ALXN, BMRN, GILD, INCY, VRTX, XBI… Update 3/23

Biotech Stocks Will Need To Rebuild Confidence With Momentum Gone Damage on Friday 3/21 was considerable but most indices/ETFs are above 2014 Feb 6 low: FBIOX ($206.4) Up 13.6% YTD, FEB 5 low $196.24 IBB ($246)  Up 8.35% YTD, FEB 6 low $237. PBE ($43.33) Up 16.94% YTD, FEB 5 low $40.32 XBI ($153) Up 17.6% […]

Continue Reading 0

Rayno Life Science Stocks Rally: Green Screen… IBB UP 2.5% Update

Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer and 42% with pre-cancerous lesions. (See detailed data). 2015 revenue forecasts from […]

Continue Reading 0

March Biotech Sell-Off: ETF Watch… XBI vs FBIOX

XBI Outperforms FBIOX YTD Many biotech stocks sold off today despite a strong market on weak volume as industrials and tech were up about 1.4%. Watch the ETFs compared to Fidelity FBIOX because the sector is more volatile this month. Here is a chart comparing three ETFs: XBI took off in January racing ahead of […]

Continue Reading 0

Sierra SnowBlog.. St. Paddys Day Forecast..Storm by Month End

It has been a warm and dry snow season in the Sierras but the Mammoth season was saved  by two decent storms in February with 68.5 inches bringing the season total to 158 in of snow.Last year another dry season dropped 308 in with a big December.The next mark is 2011-12 with only 263 in and […]

Continue Reading 0

Biotech Bull Market Consolidation Phase-Profit Taking Picks Up.. St. Paddy’s Green Update 3/17

March 17 Update –GREEN DAY  with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%, Biogen Idec (BIIB $345) up 3.8%, Gilead (GILD $76); Rayno Life Science […]

Continue Reading 0

Rayno Life Science Stocks Rally On A Choppy Day: ALXN, AMGN, BIIB, PCYC

Mini-Rally in Life Science Stocks— Update 10p PDT Biotech stocks recovered off their am lows today with major ETFs  (FBT,IBB,XBI ($161.45) up about 0.3% and within 5% of highs. Over the past week or so biopharma stocks have been weak with a “topping” process evident in late February.  Volatility has increased with daily swings and some mid-cap […]

Continue Reading 0

Update: Sell-Off In Biopharmaceutical Stocks- BIIB, PCYC, REGN

Big Large Cap Winners Down-Volatilty Increasing ETFS: IBB $257 down 1.57%, PBE $45.25 down 1.2% , XBI $159.7 down 1.17% The profit taking which actually began last Friday and, after a brief recovery, resumed yesterday accelerating today. Large caps are leading the way down. Notable losers within the Rayno Portfolio are: Biogen Idec (BIIB $326.27) […]

Continue Reading 0